TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03825705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor
Study: NCT04116255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandibular oral occlusal splint
Description: The panoramic open-mouth and close-mouth radiographs of the first group(splint group) were taken, and intraoral and extraoral examinations were performed by an experienced dentist that also examined the radiographs. The upper jaw of the patients was measured with an alginate impression material, to obtain a hard plaster model. Then, using these models, a vacuum plate machine made a customized mandibular oral occlusal splint suitable for each patient's teeth. The suitability of the splints was checked and confirmed by the dentist on the first and seventh days of use. The patients were asked to use these splints at night (for at least six hours) throughout the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporomandibular joint Exercises
Description: This program was created by combining patient training and a home exercise program. The exercise program consisted of slow passive and active mouth opening and closing exercises, isometric masseter exercises, mouth stretching exercises, and resistant mouth opening and closing exercises. Each exercise set was administered twice a day, and each movement was undertaken for 10 seconds and repeated 15 times. The training was given by an experienced physical medicine and rehabilitation expert over approximately 45 minutes. The exercise program was demonstrated for the patients in front of a mirror, and each exercise was performed by a set of patients under the supervision of a doctor. A training document including the written exercise program was to the patients in the exercises group.
Study: NCT03505333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional suture
Description: we use Liga-sure device for hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional suture
Description: we use Liga-sure device for hysterectomy
Study: NCT02320188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: This study aimed to determine the muscle effects of ECC training, with the primary outcome being the knee extensor strength gain at 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric exercise
Description: The purpose of the study is to determine in a randomized controlled trial (RCT), the efficacy of eccentric exercise training in restoring muscle mass and function in patients with rheumatoid cachexia.
Study: NCT03985735

Intervention type: DRUG
Intervention: General anesthesia
Description: For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.

Intervention type: DRUG
Intervention: General anesthesia
Description: For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.
Study: NCT03014466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Video Projector
Description: Bed mounted video projector that is used to play videos of the patient's choosing prior to induction of anesthesia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Use of Video Tablet
Description: 7 inch video tablet that is used for displaying videos of the patient's choosing prior to induction of anesthesia
Study: NCT02133573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Crinone is supplied in a single use, disposable, white polypropylene vaginal applicator with a teal twist-off cap. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide. Crinone 8% is administered vaginally at a dose of 90 mg twice daily. The rounded tip of the applicator is inserted into the vagina. After insertion, the plunger is pushed to release the gel into the vagina. The applicator is removed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal lubricant
Description: Replens Long-Lasting Moisturizer is supplied in pre-filled, sealed and individually wrapped applicators.Replens Long-Lasting Moisturizer will also be dosed at one applicator intravaginally twice daily.
Study: NCT02526914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin
Description: Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: di-sodium hydrogen phosphate, critic acid, sodium chloride, glycerin, benzalkonium chloride and aqua bidest.
Study: NCT02188966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geographic Information System
Description: GIS data is delivered by SimaTech Enterprise System communicating via the mobile network and TETRA (in Denmark called SINE). It is developed as a Java Enterprise application and is executed on a JBOSS application platform
Study: NCT04041193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIDERA^B
Description: The group will receive a kit home-based (a tablet home, access to a daily individualized training program). Five sessions for a week (3 components: monitoring, motor rehabilitation acitivities, motivational support)
Study: NCT00051558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20 micrograms/day, injection, 36 months
Study: NCT04041193

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Program
Description: Usual Care program activities (paper and pencil at home)
Study: NCT00051558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate Sodium
Description: 10 mg/day, oral, 36 months
Study: NCT03845114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continous exercise
Description: 60-minute continuous exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
Study: NCT01402310

Intervention type: OTHER
Intervention: Ultrasound and digital cervical examination
Description: Cervical length by transvaginal ultrasound Bishop score by digital examination Take cervicovaginal samples
Study: NCT03229538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IV Steroid pre-operative and intra-operative
Study: NCT00051558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo, daily, 36 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Injection placebo, daily, 36 months
Study: NCT01917110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A
Study: NCT03229538

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Isotonic saline pre-operative and intra-operative
Study: NCT01917110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle
Study: NCT03696303

Intervention type: OTHER
Intervention: Urinary antigen detection assay
Description: Screening for Ag level in S. pneumoniae urinary antigen detection assay.

Intervention type: OTHER
Intervention: Urinary antigen detection assay
Description: Screening for Ag level in S. pneumoniae urinary antigen detection assay.

Intervention type: OTHER
Intervention: Urinary antigen detection assay
Description: Screening for Ag level in S. pneumoniae urinary antigen detection assay.
Study: NCT02554253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine used for induction
Study: NCT02318251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Involuntary muscle contractions
Description: Physiotherapy program focusing on involuntary pelvic floor muscle fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day). This program includes the standard physiotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voluntary muscle contractions
Description: Physiotherapy program (physiotherapy standard program) focusing on voluntary fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day).
Study: NCT02554253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol for induction
Study: NCT04547894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC09F
Description: ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.
Study: NCT00007904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Neupogen (G-CSF) given at a dose of 10 ugm/kg subcutaneously starting on day 5 and continuing until ANC \> 10,000/uL x1 day after the nadir cycles 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Patients then receive doxorubicin IV on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 160 mg/m2 given over 72 hours by continuous infusion days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: tamoxifen at a dose of 20 mg daily for 5 years after chemotherapy is completed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Patients receive paclitaxel IV continuously and cyclophosphamide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until day 14 or until blood counts recover. Treatment repeats every 21 days for 3 courses. Patients then receive doxorubicin IV on day 1 and G-CSF SC on days 2-11 every 21 days for 4 courses.
Study: NCT03845114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continous exercise
Description: 60-minute continuous exercise on the ergocycle at 60% of VO2 peak (moderate intensity).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interval exercise
Description: Participants will perform a 60-minute interval exercise on the ergocycle at 60% of VO2 peak (moderate intensity).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interval exercise
Description: Participants will perform a 60-minute interval exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
Study: NCT00007904

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Beginning 3-6 weeks after the completion of chemotherapy, patients receive radiotherapy 5 days a week for 6-7 weeks.
Study: NCT01156038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atopy patch test with food allergen
Description: Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate reaction one day later(72 hrs after applying atopy patch test)
Study: NCT03092869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feet and Ankle Mobilization
Description: A set of manual therapy mobilization in feet and ankle joints
Study: NCT03845114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduction of basal insulin by 40%
Description: Participant's insulin basal rate will be reduced by 40% 1 hour before exercise onset.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduction of basal insulin by 40%
Description: Participant's insulin basal rate will be reduced by 40% 1 hour before exercise onset.
Study: NCT03092869

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive Training
Description: A set of proprioceptive exercises oriented to improve balance abilities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Training
Description: A set of proprioceptive exercises oriented to improve balance abilities
Study: NCT02094872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytology specimen collection procedure
Description: Undergo collection of tissue and blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK 162 therapy or molecularly targeted therapy
Description: molecularly targeted therapy, MEK 162 therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic procedure
Study: NCT03845114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduction of basal insulin by 80%
Description: Participant's insulin basal rate will be reduced by 80% 1 hour before exercise onset.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduction of basal insulin by 80%
Description: Participant's insulin basal rate will be reduced by 80% 1 hour before exercise onset.
Study: NCT02950896

Intervention type: OTHER
Intervention: observational fetal heart rate monitoring
Description: Patients will have fetal heart rate monitoring
Study: NCT01691326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose
Description: 0.25 mL dose, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®; Influenza Virus Vaccine, No Preservative
Description: 0.5 mL dose, Intramuscular
Study: NCT03770507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Comparison of stationary bike and treadmill exercise among adolescents and adults

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Comparison of stationary bike and treadmill exercise among adolescents and adults
Study: NCT02128555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Ankle Replacement
Description: The joints are resurfaced with metal implants and a mobile plastic liner is placed between them as the gliding surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrodesis
Description: The remaining damaged cartilage is removed from the ends of the bone and the two bones are then held together in compression using screws, or plates until they join to become one (bone fusion), so that there is no longer any movement at that joint.
Study: NCT00103038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 Tesla Magnetic Resonance Imaging
Description: Undergo 3T MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo 3T DCE-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo 3T DSC-MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-Based Angiogram
Description: Undergo MRA
Study: NCT02135965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg of Albuterol
Description: 2mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg of Albuterol
Description: 2mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg of Albuterol
Description: 2mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg of Albuterol
Description: 2mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg of Albuterol
Description: 2mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg of Albuterol
Description: 2mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg of Albuterol
Description: 2mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg of Albuterol
Description: 4mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg of Albuterol
Description: 4mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg of Albuterol
Description: 4mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg of Albuterol
Description: 4mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg of Albuterol
Description: 4mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg of Albuterol
Description: 4mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg of Albuterol
Description: 4mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg of Albuterol
Description: 4mg of Albuterol on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg of Caffeine
Description: 100mg of caffeine on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg of Caffeine
Description: 100mg of caffeine on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg of Caffeine
Description: 100mg of caffeine on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg of Caffeine
Description: 100mg of caffeine on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg of Caffeine
Description: 100mg of caffeine on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg of Caffeine
Description: 100mg of caffeine on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg of Caffeine
Description: 100mg of caffeine on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg of Caffeine
Description: 100mg of caffeine on metabolic rate
Study: NCT03767907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based Training for Cognitive Behavioural Therapy
Description: Interactive content organized into seven modules, illustrating real-life scenarios associated with common risky situations, which illustrate the application of targeted skills and strategies
Study: NCT02094872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02094872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03470649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: Iron Isomaltoside 1000 would be intravenously administrated to treatment group after main procedure of total knee arthroplasty.
Study: NCT03767907

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment as usual will include standard psychosocial care determined to be appropriate or necessary, on an individual patient basis.
Study: NCT03185338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active commuting to/from school
Description: Active transport to/from school on foot or by bike will be promoted
Study: NCT01917318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.~During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)
Study: NCT01020175

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone marrow transplantation
Description: Patients received bone marrow transplantation
Study: NCT01917318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.~During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During 8 weeks subjects will receive oral placebo